Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCHAR: Omega-3 for Vascular Function
NCT00935766Phase 3Terminated
- Sponsor
- Denver Health
- Start
- Sep 2009
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in cardiovascular disease (CVD) (2 arms), sponsored by Denver Health. Primary endpoint: Change in Pulse Wave Velocity at 3 months. Started Sep 2009; status: terminated.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00935766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00935766.